SREBF1 and ductal breast carcinoma in situ: The elevated expression of SREBP1 and its downstream targets, such as ACLY, ACC-1, and FASN, is observed in both clinical specimens and cell lines of DCIS, suggesting a critical role in the early stages of breast tumorigenesis [74].